8-KLeadership ChangesShareholder MattersExhibits & Filings

DEXCOM INC 8-K Report, Executive Changes (May 19, 2023)

Filed May 19, 2023For Securities:DXCM

Summary

This Form 8-K filing from DexCom, Inc. (DXCM) on May 19, 2023, details significant updates to executive compensation and outlines the results of its 2023 Annual Meeting of Stockholders. The company amended its Severance and Change in Control Plan, enhancing severance benefits for its Chief Executive Officer (CEO) and other senior executives. These changes, recommended by an independent compensation consultant, aim to align Dexcom's executive compensation with peer companies and include extended salary severance, COBRA premium coverage, and increased target bonus payouts upon termination without cause or for good reason, especially during a change of control period. The filing also reports on the outcomes of the Annual Meeting, where stockholders overwhelmingly re-elected all seven director nominees, ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2023, and approved an advisory vote on executive compensation. Notably, stockholders voted to hold the advisory "say on pay" vote annually. However, a stockholder proposal regarding pay equity disclosure was rejected by a significant margin. These actions provide insights into corporate governance and executive remuneration practices at Dexcom.

Key Highlights

  • 1Dexcom has enhanced its Severance and Change in Control Plan, increasing severance benefits for its CEO and senior executives.
  • 2CEO severance upon termination without cause (outside of change of control) increased from 18 to 24 months for salary and COBRA.
  • 3Severance benefits for CEO and C-level executives during a change of control period have been significantly increased, with salary and COBRA extending to 36 months for the CEO and 24 months for other senior executives.
  • 4Bonus severance during a change of control period has been increased to 3x target bonus for the CEO and 2x target bonus for senior executives.
  • 5All seven director nominees were re-elected to the Board of Directors at the 2023 Annual Meeting of Stockholders.
  • 6Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2023.
  • 7Stockholders approved the advisory vote on executive compensation and voted to hold this 'say on pay' vote annually.
  • 8A stockholder proposal for pay equity disclosure was rejected by the majority of shareholders.

Frequently Asked Questions

The amendments increase salary severance and COBRA premium coverage periods for the CEO and senior executives, particularly in cases of termination without cause or for good reason, especially during a change of control. Bonus severance payouts have also been increased under specific termination scenarios.

All seven director nominees presented at the 2023 Annual Meeting of Stockholders were re-elected by the holders of Dexcom's common stock, with each receiving a substantial majority of votes in favor.

Stockholders voted in favor of the advisory resolution on compensation paid to Dexcom's named executive officers. Furthermore, the Board determined, based on the vote, that the 'say on pay' vote will be held annually.

The stockholder proposal regarding pay equity disclosure was rejected by the holders of Dexcom's common stock, with a larger number of shares voting against it than in favor.